This phase I trial studies the side effects and best dose of EphA2 siRNA in treating patients
with solid tumors that have spread to other places in the body and usually cannot be cured or
controlled with treatment (advanced) or have come back after a period of improvement
(recurrent). EphA2-targeting DOPC-encapsulated siRNA may slow the growth of tumor cells by
shutting down the activity of a gene that causes tumor growth.